Stay Up to Date
Breaking News,
Updates, & More
Click Here to

Selective RET Inhibitor, BLU-667, Hits the Target in Patients with Lung or Thyroid Cancers

TOP - November 2018, Vol 11, No 3 - Emerging Therapies
Phoebe Starr

novel oral agent (BLU-667) that targets RET genetic alterations, achieved durable disease control and was safe in patients with lung or thyroid cancers and RET mutations, as demonstrated by the first-in-human phase 1 clinical trial ARROW.

“Tumor reductions and durable responses were observed in most patients, especially those whose cancers progressed with chemotherapy and multikinase inhibitors,” said lead investigator Vivek Subbiah, MD, Associate Medical Director, Clinical Center for Targeted Therapy, M.D. Anderson Cancer Center, Houston, TX.

“Our study reported an overall response rate of 37% for RET-driven cancers with responses of 50% for RET-
fusion non–small-cell lung cancer and 40% for RET-mutant medullary thyroid cancer,” Dr Subbiah said at the 2018 AACR meeting. The study was simultaneously published online (Subbiah V, et al. Cancer Discov. 2018;8:836-849).

“Overall, the data show that ­precision targeted therapy with next-generation kinase inhibitors can have a powerful impact for patients with RET-driven cancers. By offering a highly selective medicine tailored for this oncogenic driver, we hope this new therapy will enable patients to benefit from the recent advances in genomic profiling that have revolutionized treatment options for patients with kinase-driven disease,” Dr Subbiah said.

The news was greeted with enthusiasm. Experts noted that currently no drugs are approved by the US Food and Drug Administration specifically for RET-driven cancers, and a RET-targeted agent fills an unmet need.

RET mutation is found in approximately 50% of patients with medullary thyroid cancer, 20% of those with papillary thyroid cancer, and 1% to 2% of patients with non–small-cell lung cancer (NSCLC). BLU-667 is a highly selective targeted drug for RET-mutated cancers; it is 100 times more selective for RET than for other kinases. Theoretically, it should have fewer side effects than multikinase inhibitors.

The ARROW Study

The ARROW clinical trial enrolled 53 patients with advanced, RET-driven (ie, RET mutation or RET fusion) cancer who were ineligible for surgery—29 patients had medullary thyroid cancer, 19 had NSCLC, 2 had papillary thyroid cancer, and 3 other RET-driven cancers were involved. All patients did not respond to ≥1 previous therapies. The doses of BLU-667 ranged from 30 mg to 600 mg. The maximum tolerated dose was 400 mg daily.

BLU-667 exhibited broad antitumor activity. The best overall response rate (ORR) was 37% in the 30 patients who received ≥60 mg and who had ≥1 postbaseline response assessments. Patients with NSCLC or with medullary thyroid cancer had the best ORRs, 45% and 32%, respectively. Responses were observed in all tumor types, genotypes, and previously treated patients.

The safety and toxicity associated with BLU-667 were acceptable, with mostly grade 1 adverse events and no grade 4 or 5 events.

“Today, 41 of the 53 patients remain on study. This is fantastic for a first-in-human trial,” Dr Subbiah commented.

A global phase 2 clinical trial will enroll previously treated patients with multiple advanced, RET-driven cancer types.

Expert Commentary

“The data from the study are encouraging. BLU-667 is active in lung and thyroid cancer in TKI [tyrosine kinase inhibitor]-naïve and multikinase inhibitor pretreated patients....We saw that the drug was rapidly active in 1 patient with brain metastases. Hopefully, we will see this confirmed in the future,” said Alexander E. Drilon, MD, Clinical Director, Early Drug Development Service, Memorial Sloan Kettering Cancer Center, New York City, who discussed this study.

“Response rates are a tie between multikinase inhibitors and BLU-667, and we don’t have progression-free survival. Stay tuned for the central nervous activity of this drug. Hands down, BLU-667 is more tolerable than multikinase inhibitors, so the verdict is that I have to give it a ‘win,’” Dr Drilon added. l

Related Items
Adding Immunotherapy to Chemotherapy Extends Survival in Metastatic Triple-Negative Breast Cancer
Phoebe Starr
TOP - February 2019, Vol 12, No 1 published on January 29, 2019 in Breast Cancer, Immunotherapy
Targeted Therapy Has Significant Activity as Second-Line Treatment of Cholangiocarcinoma with FGFR Mutations
TOP - February 2019, Vol 12, No 1 published on January 29, 2019 in Emerging Therapies
Nelarabine Therapy Up Front Boosts Survival in T-Cell Leukemia and Lymphoma
Phoebe Starr
TOP - November 2018, Vol 11, No 3 published on November 21, 2018 in Leukemia
TLR9 Agonist plus Immunotherapy May Overcome Resistance to PD-1 Inhibition
Phoebe Starr
TOP - November 2018, Vol 11, No 3 published on November 21, 2018 in Emerging Therapies
Less Is More: 6 Months of Trastuzumab Treatment Equivalent to 12 Months in HER2-Positive Breast Cancer
Phoebe Starr
TOP - November 2018, Vol 11, No 3 published on November 21, 2018 in Breast Cancer
LOXO-292 Highly Effective in RET-Positive Cancers
Web Exclusives published on October 9, 2018 in Emerging Therapies
With Access to Care, Black Men in the United States Have Same Prostate Cancer Outcomes as White Men
Phoebe Starr
TON - September 2018, Vol 11, No 4 published on September 19, 2018 in Prostate Cancer
A Home Run for Pembrolizumab plus Chemotherapy Combination in Newly Diagnosed Metastatic Non–Small-Cell Lung Cancer
Phoebe Starr
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Lung Cancer
CAR T-Cell Manufacturing Process Depends on Good-Quality T-Cells
Phoebe Starr
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Immunotherapy
Acquired HER2 Mutations in Metastatic Breast Cancer Confer Resistance to ER-Directed Therapy
Phoebe Starr
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Breast Cancer
Last modified: December 4, 2018